The price of Incruse Ellipta can vary significantly depending on factors such as insurance coverage, pharmacy location, and whether a prescription discount is applied. Without specific insurance details or pharmacy information, providing an exact price is not feasible.
How much does Incruse Ellipta cost without insurance?
The retail price of Incruse Ellipta averages around $500 to $600 for a 30-day supply. This price reflects the cost without any insurance or discount programs. Actual prices can fluctuate based on the pharmacy and region [1].
Are there ways to get a discount on Incruse Ellipta?
Yes, several options may reduce the out-of-pocket cost of Incruse Ellipta.
* Manufacturer Coupons and Savings Cards: GSK, the manufacturer of Incruse Ellipta, often provides savings cards for eligible commercially insured patients, which can lower the monthly cost to as little as $25 [1].
* Patient Assistance Programs: For eligible uninsured or underinsured patients, GSK may offer a patient assistance program that provides medication at a reduced cost or for free.
* Online Pharmacies and Discount Cards: Comparison shopping at different pharmacies or using online discount drug cards can sometimes yield lower prices.
What is the typical cost of Incruse Ellipta with insurance?
The cost of Incruse Ellipta with insurance depends on the specific formulary of the insurance plan. Many insurance plans cover Incruse Ellipta, but copays can range from a small amount to a higher percentage of the drug's cost. Some plans may require prior authorization or step therapy, where a different medication must be tried first. Checking with your insurance provider is the best way to determine your copay.
What is Incruse Ellipta used for?
Incruse Ellipta (umeclidinium) is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis [2]. It works by relaxing the muscles around the airways in the lungs, making it easier to breathe. It is not a rescue inhaler for sudden breathing problems [2].
What is the patent status of Incruse Ellipta?
Information on the specific patent expiry dates for Incruse Ellipta is available through resources like DrugPatentWatch.com [3]. DrugPatentWatch tracks patents for pharmaceutical products, which can indicate when generic versions might become available, potentially impacting pricing.
How does Incruse Ellipta compare to other COPD inhalers?
Incruse Ellipta is one of several treatment options for COPD. It is often used in combination with other medications, such as long-acting beta-agonists (LABAs) or inhaled corticosteroids (ICS), to provide more comprehensive symptom control. Other LAMAs, LABAs, and combination inhalers are also available, and the choice of medication depends on individual patient needs and physician recommendations.
Sources:
[1] https://www.goodrx.com/incruse-ellipta
[2] https://www.incruseellipta.com/
[3] https://drugpatentwatch.com/